학술논문
First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) in patients (pts) with microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): 64-month (mo) follow-up from CheckMate 142.
Document Type
Article
Author
Lenz, Heinz-Josef; Overman, Michael J.; Van Cutsem, Eric; Limon, Maria Luisa; Wong, Ka Yeung Mark; Hendlisz, Alain; Aglietta, Massimo; Garcia-Alfonso, Pilar; Neyns, Bart; Gelsomino, Fabio; Cardin, Dana Backlund; Dragovich, Tomislav; Shah, Usman; McCraith, Stephen; Wang, Rui; Lei, Ming; Yao, Jin; Jin, Lixian; Lonardi, Sara
Source
Journal of Clinical Oncology; 2024 Supplement 3, Vol. 42, p97-97, 235p
Subject
Language
ISSN
0732183X